Lipid-lowering therapies in development

Expert Opinion on Investigational Drugs

Volumn 13, Issue 11, 2004, Pages 1405-1418

  Wierzbicki, Anthony S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Cholesterol; Drug; HDL C; LDL C; Lipid; New agent

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID; CERIVASTATIN; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID TRANSFER PROTEIN; MEVINOLIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PITAVASTATIN; PRAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; SQUALENE SYNTHASE INHIBITOR; UNINDEXED DRUG; VERAPAMIL;

ABETALIPOPROTEINEMIA; ATAXIA; ATHEROSCLEROSIS; CLINICAL STUDY; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG TOLERABILITY; DRUG USE; FATTY LIVER; HUMAN; KIDNEY DYSFUNCTION; NONHUMAN; POLYNEUROPATHY; PROTEINURIA; RETINOPATHY; REVIEW; TREATMENT OUTCOME;

CHOLESTEROL, LDL; CLINICAL TRIALS; DRUG DESIGN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; LIPIDS; LIPOPROTEIN(A);

EID: 8844285172     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.11.1405     Document Type: Review

References (116)

1. BUCHER HC, GRIFFITH LE, GUYATT GH: Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler. Thromb. Vasc. Biol. (1999) 19:187-195.
2. SACKS FM: The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am. J. Cardiol. (2002) 90 139-143.
3. CHAPMAN MJ, ASSMAN G, SHEPHERD J, SIRTORI C, on behalf of The European Consensus Panel on HDL-C: Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr. Med. Res. Opin. (2004) 20:1253-1268.
4. WIERZBICKI AS, POSTON R, FERRO A: The lipid and non-lipid effects of statins. Pharmacol. Ther. (2003) 99:95-112.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA (2001) 285:2486-2497.
6. WARNICK GR, MYERS GL, COOPER GR, RIFAI N: Impact of the third cholesterol report from the adult treatment panel of the national cholesterol education program on the clinical laboratory. Clin. Chem. (2002) 48:11-17.
7. WIERZBICKI AS, MIKHAILIDIS DP: Beyond LDL-C-the importance of raising HDL-C. Curr. Med. Res. Opin. (2002) 18:36-44.
8. WIERZBICKI AS, MIKHAILIDIS DP, WRAY R et al.: Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr. Med. Res. Opin. (2002) 19:155-168.
9. HEINONEN OP, HUTTUNEN JK, MANNINEN V et al.: The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up. J. Intern. Med. (1994) 235:41-49.
10. RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. (1999) 341:410-418.
11. HAIM M, BENDERLY M, BRUNNER D et al.: Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation (1999) 100:475-482.
12. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N. Engl. J. Med. (1997) 336 153-162.
13. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7-22.
14. FOX KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet (2003) 362:782-788.
15. ATHYROS VG, MIKHAILIDIS DP, PAPAGEORGIOU AA et al.: Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J. Hum. Hypertens. (2004) (In press).
16. BAYS HE, McGOVERN ME: Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev. Cardiol. (2003) 6:179-188.
17. BAYS HE, DUJOVNE CA, McGOVERN ME et al.: Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am. J. Cardiol. (2003) 91:667-672.
18. CANNER PL, BERGE KG, WENGER NK et al.: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. (1986) 8:1245-1255.
19. STEWART WJ, HOOGWERF BJ: Lipid-lowering therapy after coronary artery bypass surgery: the Post-CABG trial. Cleve. Clin. J. Med. (1997) 64:347-351.
20. McTAGGART F, BUCKETT L, DAVIDSON R et al.: Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am. J. Cardiol. (2001) 87:28B-32B.
21. OLSSON AG, PEARS J, McKELLAR J, MIZAN J, RAZA A: Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am. J. Cardiol. (2001) 88:504-508.
22. CHONG PH, YIM BT: Rosuvistatin for the treatment of patients with hypercholesterolemia. Ann. Pharmacother. (2002) 36 93-101.
23. WOLFE SM: Dangers of rosuvastatin identified before and after FDA approval. Lancet (2004) 363:2189-2190.
24. VIDT DG, CRESSMAN MD, HARRIS S, PEARS JS, HUTCHINSON HG: Rosuvastatin-induced arrest in progression of renal disease. Cardiology (2004) 102:52-60.
25. KAJINAMI K, MABUCHI H, SAITO Y: NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opin. Investig. Drugs (2000) 9:2653-2661.
26. NESS GC, ZHAO Z, KELLER RK: Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7 α hydroxylase. Arch. Biochem. Biophys. (1994) 311:277-285.
27. HIYOSHI H, YANAGIMACHI M, ITO M et al.: Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. Eur. J. Pharmacol. (2001) 431:345-352.
28. WIERZBICKI AS: Editorial: Statins: myalgia and myositis. Br. J. Cardiol. (2002) 9:193-194.
29. SHARMA A, SLUGG PH, HAMMETT JL, JUSKO WJ: Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J. Clin. Pharmacol. (1998) 38:1116-1121.
30. BERGSTROM JD, KURTZ MM, REW DJ et al.: Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. USA (1993) 90 80-84.
31. AMIN D, RUTLEDGE RZ, NEEDLE SN et al.: RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J. Pharmacol. Exp. Ther. (1997) 281:746-752.
32. UGAWA T, KAKUTA H, MORITANI H et al.: YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br. J. Pharmacol. (2000) 131 63-70.
33. WIERZBICKI AS: Imidazole derivatives as cholesterol-lowering agents. Int. J. Cardiol. (2003) 90:145-146.
34. TAGHIBIGLOU C, VAN IDERSTINE SC, KULINSKI A, RUDY D, ADELI K: Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor. Biochem. Pharmacol. (2002) 63:349-360.
35. CHANG TY, CHANG CC, LIN S, YU C, LI BL, MIYAZAKI A: Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2. Curr. Opin. Lipidol. (2001) 12:289-296.
36. BURNETT JR, WILCOX LJ, TELFORD DE et al.: Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J. Lipid Res. (1999) 40:1317-1327.
37. DELSING DJ, OFFERMAN EH, VAN DUYVEN VOORDE W et al.: Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation (2001) 103:1778-1786.
38. BOCAN TM, MUELLER SB, BROWN EQ et al.: HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit. Atherosclerosis (1998) 139:21-30.
39. INSULL W Jr, KOREN M, DAVIGNON J et al.: Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis (2001) 157:137-144.
40. TARDIF JC, GREGOIRE J, LESPERANCE, J et al.: Design features of the avasimibe and progression of coronary lesions assessed by intravascular ultrasound (A-PLUS) clinical trial. Am. Heart J. (2002) 144:589-596.
41. BURNETT JR, HUFF MW: Avasimibe Pfizer. Curr. Opi. Investig. Drugs (2002) 3:1328-1333.
42. SAHI J, MILAD MA, ZHENG X et al.: Avasimibe induces CYP3A4 and MDR1 gene expression through activation of the pregnane X receptor. J. Pharmacol. Exp. Ther. (2003) 306(3):1027-1034.
43. WIERZBICKI AS: Atorvastatin. Expert Opin. Pharmacother. (2001) 2:819-830.
44. JAMIL H, CHU CH, DICKSON JK Jr et al.: Evidence that microsomal triglyceride transfer protein is limiting in the production of apolipoprotein B-containing lipoproteins in hepatic cells. J. Lipid Res. (1998) 39:1448-1454.
45. WETTERAU JR, GREGG RE, HARRITY TW et al.: An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science (1998) 282:751-754.
46. SHIOMI M, ITO T: MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur. J. Pharmacol. (2001) 431:127-131.
47. JIN FY, KAMANNA VS, KASHYAP ML: Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler. Thromb. Vasc. Biol. (1999) 19:1051-1059.
48. GYLLING H, MIETTINEN TA: Cholesterol reduction by different plant stanol mixtures and with variable fat intake. Metabolism (1999) 48:575-580.
49. WASAN KM, ZAMFIR C, PRITCHARD PH, PEDERSON RA: Influence of Phytostanol Phosphoryl Ascorbate (FM-VP4) on insulin resistance, hyperglycemia, plasma lipid levels, and gastrointestinal absorption of exogenous cholesterol in Zucker (fa/fa) fatty and lean rats. J. Pharm. Sci. (2003) 92:281-288.
50. LEITERSDORF E: Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management. Int. J. Clin. Pract. (2002) 56:116-119.
51. ALTMANN SW, DAVIS HR Jr et al.: Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science (2004) 303:1201-1204.
52. SMART EJ, DE ROSE RA, FARBER SA: Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc. Natl. Acad Sci. USA (2004) 101:3450-3455.
53. BALLANTYNE CM, HOURI J, NOTARBARTOLO A et al.: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation (2003) 107:2409-2415.
54. KOSOGLOU T, STATKEVICH P, FRUCHART JC et al.: Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr. Med. Res. Opin. (2004) 20:1197-207.
55. GAGNE C, GAUDET D, BRUCKERT E: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation (2002) 105:2469-2475.
56. BAYS HE, MOORE PB, DREHOBL MA et al.: Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two Phase II studies. Clin. Ther. (2001) 23 1209-1230.
57. MAURO VF, TUCKERMAN CE: Ezetimibe for management of hypercholesterolemia. Ann. Pharmacother. (2003) 37:839-848.
58. WIERZBICKI AS, DOHERTY E, LUMB PJ, CHIK G, CROOK MA: Efficacy of ezetimibe in statin-resistant and statin-intolerant patients with familial hyperlipidaemias. Curr. Med. Res. Opin. (2004) (in press ).
59. BALLANTYNE CM, BLAZING MA, KING TR, BRADY WE, PALMISANO J: Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol. (2004) 93:1487-1494.
60. BUCHWALD H, VARCO RL, MATTS JP et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N. Engl. J. Med. (1990) 323:946-955.
61. Pamaqueside. CP 148623. Drugs RD (2002) 3 175-176.
62. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA (1984) 251:351-364.
63. INSULL W Jr, TOTH P, MULLICAN W et al.: Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin. Proc. (2001) 76:971-982.
64. HUNNINGHAKE D, INSULL W Jr, TOTH P, DAVIDSON D, DONOVAN JM, BURKE SK: Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis (2001) 158 407-416.
65. KNAPP HH, SCHROTT H, MA P et al.: Efficacy and safety of cambination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am. J. Med. (2001) 110:352-360.
66. EDWARDS PA, KAST HR, ANISFELD AM: BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. (2002) 43:2-12.
67. +/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol. (1998) 18:1304-1311.
68. ROBINS SJ, COLLINS D, WITTES JT et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA (2001) 285 1585-1591.
69. CORNWELL PD, DE SOUZA AT, ULRICH RG: Profiling of hepatic gene expression in rats treated with fibric acid analogs. Mutat. Res. (2004) 549:131-145.
70. YIN W, TSUTSUMI K: Lipoprotein lipase activator NO-1886. Cardiovasc. Drug Rev. (2003) 21:133-142.
71. YIN W, YUAN Z, TSUTSUMI K et al.: A lipoprotein lipase-promoting agent, NO-1886, improves glucose and lipid metabolism in high fat, high sucrose-fed New Zealand white rabbits. Int. J. Exp. Diabetes Res. (2003) 4:27-34.
72. FERRE P: The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes (2004) 53(Suppl. 1):S43-S50.
73. GUPTA RA, WANG D, KATKURI S, WANG H, DEY SK, DUBOIS RN: Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat. Med. (2004) 10:245-247.
74. IDZIOR-WALUS B, SIERADZKI J, ROSTWOROWSKI W et al.: Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur. J. Clin. Invest. (2000) 30:871-878.
75. LOHRAY BB, LOHRAY VB, BAJJI AC et al.: (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J. Med. Chem. (2001) 44:2675-2678.
76. SHIBATA T, TAKEUCHI S, YOKOTA S, KAKIMOTO K, YONEMORI F, WAKITANI K: Effects of peroxisome proliferator-activated receptor-α and -γ agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br. J. Pharmacol. (2000) 130:495-504.
77. ETGEN GJ, OLDHAM BA, JOHNSON WT et al.: A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-α/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes (2002) 51:1083-1087.
78. YAJIMA K, HIROSE H, FUJITA H et al.: Combination therapy with PPARγ and PPARα agonists increases glucose-stimulated insulin secretion in db/db mice. Am. J. Physiol. Endocrinol. Metab. (2003) 284:E966-E971.
79. CALKIN AC, THOMAS MC, COOPER ME: MK-767. Kyorin/Banyu/Merck. Curr. Opin. Investig. Drugs (2003) 4:444-448.
80. ERICSSON H, HAMREN B, BERGSTRAND S et al.: Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator activated receptor {/{γ} agonist, after a single oral and intravenous dose in humans. Drug Metab. Dispos. (2004) 32:923-929.
81. SAAD MF, GRECO S, OSEI K et al.: Ragaglitazar improves glycemic control and lipid profile in Type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open piogtitazone arm. Diabetes Care (2004) 27:1324-1329.
82. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet (1999) 354 447-455.
83. MARCHIOLI R, BARZI F, BOMBA E et al.: Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation (2002) 105:1897-903.
84. MORTON RE: Cholesteryl ester transfer protein and its plasma regulator: lipid transfer inhibitor protein. Curr. Opin. Lipidol. (1999) 10:321-327.
85. OKAMOTO H, YONEMORI F, WAKITANI K, MINOWA T, MAEDA K, SHINKAI H: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature (2000) 406:203-207.
86. HUANG Z, INAZU A, NOHARA A, HIGASHIKATA T, MABUCHI H: Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin. Sci. (2002) 103:587-594.
87. DE GROOTH GJ, KUIVENHOVEN JA, STALENHOEF AF et al.: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized Phase II dose-response study. Circulation (2002) 105:2159-2165.
88. CLARK RW, SUTFIN TA, RUGGERI RB et al.: Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. (2004) 24:490-497.
89. BROUSSEAU ME, SCHAEFER EJ, WOLFE ML et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. (2004) 350:1505-1515.
90. DAVIDSON MH, MAKI K, UMPOROWICZ D, WHEELER A, RITTERSHAUS C, RYAN U: The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis (2003) 169:113-120.
91. SRIVASTAVA RA, SRIVASTAVA N: High density lipoprotein, apolipoprotein A-I, and coronary artery disease. Mol. Cell Biochem. (2000) 209:131-144.
92. NEWTON RS, KRAUSE BR: HDL therapy for the acute treatment of atherosclerosis. Atheroscler. Suppl. (2002) 3:31-38.
93. CHIESA G, SIRTORI CR: Apolipoprotein A-I Milano: current perspectives. Curr. Opin. Lipidol. (2003) 14:159-163.
94. KLON AE, JONES MK, SEGREST JP, HARVEY SC: Molecular belt models for the apolipoprotein A-I Paris and Milano mutations. Biophys. J. (2000) 79:1679-1685.
95. CHIESA G, MONTEGGIA E, MARCHESI M et al.: Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ. Res. (2002) 90 974-980.
96. NISSEN SE, TSUNODA T, TUZCU EM et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes a randomized controlled trial. JAMA (2003) 290:2292-300.
97. MERTENS A, HOLVOET P: Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. (2001) 15:2073-2084.
98. PACKARD CJ, O'REILLY DS, CASLAKE MJ et al.: Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. (2000) 343:1148-1155.
99. BLACKIE JA, BLOOMER JC, BROWN MJ et al.: The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A(2). Bioorg. Med. Chem. Lett. (2003) 13:1067-1070.
100. SHLIPAK MG, SIMON JA, VITTINGHOFF E et al.: Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA (2000) 283:1845-1852.
101. BERGLUND L, CARLSTROM K, STEGE R et al.: Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males. J. Clin. Endocrinol. Metab. (1996) 81:2633-2637.
102. SHARP RJ, PERUGINI MA, MARCOVINA SM, McCORMICK SP: A synthetic peptide that inhibits lipoprotein(a) assembly. Arterioscler. Thromb. Vasc. Biol. (2003) 23:502-507.
103. SUNDELL CL, SOMERS PK, MENG CQ et al.: AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J. Pharmacol. Exp. Ther. (2003) 305:1116-1123.
104. TARDIF JC: Clinical results with AGI-1067: a novel antioxidant vascular protectant. Am. J. Cardiol. (2003) 91 41A-49A.
105. TARDIF JC, GREGOIRE J, SCHWARTZ L et al.: Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation (2003) 107:552-558.
106. WALD NJ, LAW MR: A strategy to reduce cardiovascular disease by more than 80%. Br. Med. J. (2003) 326:1419.
107. The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators. Arch. Intern. Med. (1992) 152:1399-1410.
108. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet (1984) 2:600-604.
109. HUTTUNEN JK, HEINONEN OP, MANNINEN V et al.: The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J. Intern. Med. (1994) 235:31-39.
110. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383-1389.
111. SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med (1996) 335:1001-1009.
112. SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med (1995) 333:1301-1307.
113. ATHYROS VG, PAPAGEORGIOU AA, MERCOURIS BR et al.: Treatment with atorvastatin to the National Cholesterol Educational Program Goals versus Usual Care in Secondary Coronary Heart Disease Prevention. The Greek Atorvastatin and Coronary-Heart-disease Evaluation (GREACE) Study. Curr. Med Res. Opin. (2002) 18:220-228.
114. SHEPHERD J, BLAUW GJ, MURPHY MB et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360:1623-1630.
115. SEVER PS, DAHLOF B, POULTER NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361 1149-1158.
116. COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN et al.: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet (2004) 364:685-696.